Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models
IntroductionIntraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity. We carried out a systematic review to compare tumor response, measured by tumor weight and volume, between intraperitoneal chemotherapy de...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1487376/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555169371750400 |
|---|---|
| author | Marcelo Simonsen Marcelo Simonsen Rossana Verónica Mendoza López Simone Maistro Lucas Takeshi Ikeoka Glaucia Fernanda de Lima Pereira Ademar Benévolo Lugão José Carlos Sadalla Maria Lúcia Hirata Katayama Maria Aparecida Azevedo Koike Folgueira |
| author_facet | Marcelo Simonsen Marcelo Simonsen Rossana Verónica Mendoza López Simone Maistro Lucas Takeshi Ikeoka Glaucia Fernanda de Lima Pereira Ademar Benévolo Lugão José Carlos Sadalla Maria Lúcia Hirata Katayama Maria Aparecida Azevedo Koike Folgueira |
| author_sort | Marcelo Simonsen |
| collection | DOAJ |
| description | IntroductionIntraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity. We carried out a systematic review to compare tumor response, measured by tumor weight and volume, between intraperitoneal chemotherapy delivered via drug delivery systems (DDSs) and free intraperitoneal chemotherapy in animal models of ovarian cancer. The secondary aim was to assess the toxicity of DDS-delivered chemotherapy, based on changes in animal body weight.MethodsBased on PRISMA and SYRCLE guidelines, we identified 38 studies for review, of which 20, were used in the meta-analysis. We evaluated outcome, through tumor volume and tumor weight and, toxicity, through animal weight. Analysis was based on drugs employed and treatment duration.ResultsMost studies were performed on mice. Ovarian cancer cell lines most commonly used to induce xenografts were SKOV3 (19 studies) and A2780 (6 studies). Intraperitoneal device, also known as drug delivery systems (DDS), consisted in nanoparticles, hydrogels, lipid polymer and others. The most commonly used drugs were paclitaxel and cisplatin. Most studies used as the control treatment the same chemotherapy applied free intraperitoneally and tumor response/animal weight were evaluated weekly. There was a small benefit in overall tumor reduction in animals treated with intraperitoneal chemotherapy applied through the slow release device compared with animals treated with intraperitoneal free chemotherapy, as evaluated through tumor weight - results in standardized mean difference. (-1.06; 95% CI: -1.34, -0.78) and tumor volume (-3.72; 95% CI: -4.47, -2.97), a benefit that was seen in most weekly evaluations and for most chemotherapy drugs, such as carboplatin (tumor weight: -5.60; 95% CI: -7.83, -3.37), paclitaxel (tumor weight: -1.18; 95% CI: -1.52, -0.83), and cisplatin (tumor volume: -2.85; 95% CI: -3.66, -2.04) carboplatin (tumor volume: -12.71; 95% CI: -17.35, -8.07); cisplatin (tumor volume: -7.76; 95% CI: -9.88, -5.65); paclitaxel (tumor volume: -2.85; 95% CI: -3.66, -2.04). Regarding animal weight, there was no weight reduction in animals treated with intraperitoneal chemotherapy applied through the slow-release device compared with animals treated with intraperitoneal free chemotherapy. However, significant heterogeneity was observed in some comparisons.Conclusionslow-release devices are overall safe and effective in animal models of ovarian cancer. It was not possible to evaluate which one is the most promising device to treat ovarian cancer, because many different types were used to apply chemotherapy intraperitoneally.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021224573. |
| format | Article |
| id | doaj-art-676a9de84e22493db21213a444c822cb |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-676a9de84e22493db21213a444c822cb2025-01-08T06:11:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14873761487376Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal modelsMarcelo Simonsen0Marcelo Simonsen1Rossana Verónica Mendoza López2Simone Maistro3Lucas Takeshi Ikeoka4Glaucia Fernanda de Lima Pereira5Ademar Benévolo Lugão6José Carlos Sadalla7Maria Lúcia Hirata Katayama8Maria Aparecida Azevedo Koike Folgueira9Departamento de Radiologia e Oncologia, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilGynecology and Obstetrics Department, Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, BrazilDepartamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilDepartamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilFaculdade de Medicina, Undergraduate program, Universidade de Sao Paulo (FMUSP), Sao Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilNuclear and Energy Research Institute, IPEN-Comissão Nacional de Energia Nuclear (CNEN)/SP—University of São Paulo, São Paulo, SP, BrazilDepartamento de Ginecologia e Obstetrícia, Instituto do Câncer do Estado de Sao Paulo do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, BrazilDepartamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilDepartamento de Radiologia e Oncologia, Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (HCFMUSP), Sao Paulo, SP, BrazilIntroductionIntraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity. We carried out a systematic review to compare tumor response, measured by tumor weight and volume, between intraperitoneal chemotherapy delivered via drug delivery systems (DDSs) and free intraperitoneal chemotherapy in animal models of ovarian cancer. The secondary aim was to assess the toxicity of DDS-delivered chemotherapy, based on changes in animal body weight.MethodsBased on PRISMA and SYRCLE guidelines, we identified 38 studies for review, of which 20, were used in the meta-analysis. We evaluated outcome, through tumor volume and tumor weight and, toxicity, through animal weight. Analysis was based on drugs employed and treatment duration.ResultsMost studies were performed on mice. Ovarian cancer cell lines most commonly used to induce xenografts were SKOV3 (19 studies) and A2780 (6 studies). Intraperitoneal device, also known as drug delivery systems (DDS), consisted in nanoparticles, hydrogels, lipid polymer and others. The most commonly used drugs were paclitaxel and cisplatin. Most studies used as the control treatment the same chemotherapy applied free intraperitoneally and tumor response/animal weight were evaluated weekly. There was a small benefit in overall tumor reduction in animals treated with intraperitoneal chemotherapy applied through the slow release device compared with animals treated with intraperitoneal free chemotherapy, as evaluated through tumor weight - results in standardized mean difference. (-1.06; 95% CI: -1.34, -0.78) and tumor volume (-3.72; 95% CI: -4.47, -2.97), a benefit that was seen in most weekly evaluations and for most chemotherapy drugs, such as carboplatin (tumor weight: -5.60; 95% CI: -7.83, -3.37), paclitaxel (tumor weight: -1.18; 95% CI: -1.52, -0.83), and cisplatin (tumor volume: -2.85; 95% CI: -3.66, -2.04) carboplatin (tumor volume: -12.71; 95% CI: -17.35, -8.07); cisplatin (tumor volume: -7.76; 95% CI: -9.88, -5.65); paclitaxel (tumor volume: -2.85; 95% CI: -3.66, -2.04). Regarding animal weight, there was no weight reduction in animals treated with intraperitoneal chemotherapy applied through the slow-release device compared with animals treated with intraperitoneal free chemotherapy. However, significant heterogeneity was observed in some comparisons.Conclusionslow-release devices are overall safe and effective in animal models of ovarian cancer. It was not possible to evaluate which one is the most promising device to treat ovarian cancer, because many different types were used to apply chemotherapy intraperitoneally.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42021224573.https://www.frontiersin.org/articles/10.3389/fonc.2024.1487376/fullovarian cancerdrug delivery systemsanimal modelintraperitoneal chemotherapymeta-analysis |
| spellingShingle | Marcelo Simonsen Marcelo Simonsen Rossana Verónica Mendoza López Simone Maistro Lucas Takeshi Ikeoka Glaucia Fernanda de Lima Pereira Ademar Benévolo Lugão José Carlos Sadalla Maria Lúcia Hirata Katayama Maria Aparecida Azevedo Koike Folgueira Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models Frontiers in Oncology ovarian cancer drug delivery systems animal model intraperitoneal chemotherapy meta-analysis |
| title | Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models |
| title_full | Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models |
| title_fullStr | Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models |
| title_full_unstemmed | Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models |
| title_short | Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models |
| title_sort | peritoneal chemotherapy delivery systems for ovarian cancer treatment systematic review of animal models |
| topic | ovarian cancer drug delivery systems animal model intraperitoneal chemotherapy meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1487376/full |
| work_keys_str_mv | AT marcelosimonsen peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT marcelosimonsen peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT rossanaveronicamendozalopez peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT simonemaistro peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT lucastakeshiikeoka peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT glauciafernandadelimapereira peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT ademarbenevololugao peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT josecarlossadalla peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT marialuciahiratakatayama peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels AT mariaaparecidaazevedokoikefolgueira peritonealchemotherapydeliverysystemsforovariancancertreatmentsystematicreviewofanimalmodels |